Benostan Health Products

What Benostan Health Products does

Benostan Health Products S.A. is a privately held Greek consumer healthcare company, founded in 1985 and headquartered in Vrilissia, Attiki, Greece, that develops and commercializes topical healthcare assets across six therapeutic areas: Women's Health and Gynecology, Oncology, Diabetes, Specialty Dermatology, Medical Aesthetics, and Pediatrics. The portfolio comprises 14 named products delivered as topical formulations, suppositories, ovules, and food supplements, including branded SKUs such as VITAL-V Film Forming Emulsion Ovules, Venocontract Emulsion, M-EEZE Solution (EU patented), Scar-Reeze Gel, PSO-Reeze Cream, DIABETHERB FOOT WASH, and Baby Nappy Cream. Core technology centers on a proprietary Natural Extraction Process that preserves bioactive potency from herbs and plant stem cells, combined with a topical drug delivery system that improves compound penetration through the stratum corneum. Formulations rely on ingredients documented in the American Pharmacopeia, European Pharmacopeia, and Physicians Desk Reference, supporting the company's regulatory positioning.

The business operates as a lean B2B licensing and distribution platform rather than a direct-to-consumer retailer. Benostan licenses and commercializes its formulations through pharmaceutical distribution partners that cover more than 50 countries — including Canada, USA, MENA, North Africa, Southeast Asia, and Central America — reaching a stated total addressable market of 4 billion patients. Revenue is generated primarily through licensing royalties and partner-channel product sales, with marketing mixes and target groups customized per country. Products are validated through a physician network before commercialization. Management consists of CEO Nikos Tympanidis, with no other executive team disclosed in the available material. The company reports 11-50 employees and claims 40% EBITDA margins on branded topical products with pricing flexibility compared to generics. No public listing, funding rounds, acquisitions, or parent company relationships are identified in the source data.

Name

Benostan Health Products

Legal name

BENOSTAN HEALTH PRODUCTS S.A.

Website

https://benostan.eu

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

11–50 employees

Short description

Benostan Health Products is a Greek consumer healthcare company founded in 1985 that develops proprietary topical formulations across women's health, oncology, dermatology, diabetes, medical aesthetics, and pediatrics, commercializing 14 products through pharma licensing partners in over 50 countries.

Ownership category

akta.pro rank

Product category

Topical Consumer Healthcare Products

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro industry

PRIMARYHLAIADAJ

Women’s Health (OTC Gynecologic)

Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

SECONDARYCRADAMAC

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

SECONDARYCRABAAAF

Dermocosmetics & Medical-Grade Skincare

Consumer Products & Retail/Beauty & Personal Care/Skincare

Keywords

• Topical drug delivery
• Galenical formulations
• Women's health products
• Dermatology medical devices
• Pharmaceutical licensing

Headquarters

HQ city

North Greece

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Commercialization: Benostan licenses non-prescription medicine and consumer self-care products to pharma partners. The company develops, optimizes, and commercializes galenical formulations associated with drug delivery technologies, earning licensing fees and royalties from commercialization agreements with pharma companies across 50+ countries.
2. Product Sales: Direct sales of consumer healthcare products through distribution partnerships. Products are sold via pharma distribution networks with customized marketing mix and target groups based on country specifics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Benostan develops and commercializes healthcare assets in easy-to-administer topical forms—including topical formulations, suppositories, ovules, and food supplements—across six therapeutic areas: Women's Health & Gynecology, Oncology, Diabetes, Specialty Dermatology, Medical Aesthetics, and Pediatrics. The company creates proprietary galenical formulations using its Natural Extraction Process and topical drug delivery technology, then licenses these assets to pharmaceutical distribution partners who commercialize them across more than 50 countries with a total addressable market of 4 billion patients.

Product overview

Benostan Health Products is a consumer healthcare company that develops and commercializes healthcare assets in easy-to-administer topical forms (topical formulations, suppositories, ovules, and food supplements) across six therapeutic areas: Women's Health & Gynecology, Oncology, Diabetes, Specialty Dermatology, Medical Aesthetics, and Pediatrics. The product portfolio includes 14 named products ranging from ovules for menopause symptoms (VITAL-V Film Forming Emulsion Ovules) to oncology support (M-ΕΕΖΕ Solution, DERMOSENSITIVE REPAIR CREAM), diabetes foot care (DIABETHERB FOOT WASH, Diabet-eeze), pediatric care (BENNIT KIDS SHAMPOO, Baby Nappy Cream), medical aesthetics recovery (Dermo Soothing Gel, DERMO ANTI-SPOT CREAM, Dermo Lightening Serum), dermatology treatments (Scar-Reeze Gel, PSO-Reeze Cream), and women's health products (Venocontract Emulsion, Phytoroid Cream). Products are commercialized through B2B pharma partnerships across more than 50 countries, reaching a total addressable market of 4 billion patients.

Differentiator

Problem solved

Functional benefit

Products and services

• VITAL-V Film Forming Emulsion Ovules Ovules specifically developed for the relief of irritation and dryness of the intimate area, symptoms often associated with menopause. Distributed through pharma partners.
• Venocontract Emulsion Novel formula that soothes heavy, tired legs and relieves common symptoms caused by varicose veins. Distributed through pharma partners.
• Phytoroid Cream A soothing cream that assists in relief from common symptoms of hemorrhoids; also ideal for use after episiotomy. Distributed through pharma partners.
• DIABETHERB FOOT WASH Mild formula gel designed to support the hygiene and comfort of the diabetic foot; refreshes, tones, and helps maintain the skin's natural defenses. Distributed through pharma partners.
• Diabet-eeze Film Forming Emulsion Film-forming emulsion designed to hydrate and improve skin elasticity on the diabetic foot; supports the skin's barrier and microcirculation of the lower limbs. Distributed through pharma partners.
• BENNIT KIDS SHAMPOO Formula designed to support removal of head lice while helping soothe scalp discomfort; gentle on the skin and suitable for repeated use. Distributed through pharma partners.
• Baby Nappy Cream Soft, water-resistant cream that protects baby's sensitive skin during diaper changes; supports the skin's natural balance and helps soothe irritated skin. Distributed through pharma partners.
• Dermo Soothing Gel Formula designed to address skin bruises and inflammation, supporting skin recovery between and after aesthetic procedures. Distributed through pharma partners.
• DERMO ANTI-SPOT CREAM Formula for issues associated with skin pigmentation; moisturizes and reduces dark spots with a lightening effect. Distributed through pharma partners.
• Dermo Lightening Serum Formula for issues associated with skin redness, discoloration and inflammation. Distributed through pharma partners.
• Scar-Reeze Gel Silicone-based gel ideal for scars caused by injuries, burns, surgical procedures or acne; free from corticosteroids and anesthetics. Distributed through pharma partners.
• PSO-Reeze Cream Non-invasive medical device designed to manage the skin micro-environment in cases of irritation and inflammation associated with psoriasis. Distributed through pharma partners.
• DERMOSENSITIVE REPAIR CREAM Gentle care cream for sensitive and fragile skin, suitable for individuals undergoing demanding oncology treatments and experiencing skin dryness, tightness, or redness. Distributed through pharma partners.
• M-EEZE Solution (Mouth Rinse) EU patented mouth rinse and artificial saliva that manages symptoms of dry mouth during radiation therapy, chemotherapy, or any other ionized treatment. Distributed through pharma partners.

Quantifiable outcome

• 40% EBITDA margins on products
• +2 more outcomes

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Pharma Distribution Partners (Multiple Companies)coreChannel Partner/ Reseller/ DistributorBenostan collaborates with multiple pharmaceutical companies serving as distribution and commercialization partners. These partners cover more than 50 countries with significant presence in South East Asia, North Africa, MENA, North & Central America. Partners have endorsed Benostan's business model and products. The relationship involves licensing of Benostan's formulations for local distribution and commercialization.

Scale indicators4 records

Recent moves2 records

Expansion highlights4 records

Direct peers

• Galderma: Specialty dermatology pharma company with a portfolio spanning acne, psoriasis, rosacea, and aesthetic dermatology — directly comparable therapeutic focus to Benostan's dermatology and aesthetics verticals.
• Helsinn Healthcare: Swiss specialty pharma that develops and out-licenses therapeutics globally, including supportive oncology care — closely comparable business model of developing formulations and licensing to distribution partners.
• Pierre Fabre Dermatologie: French dermocosmetics group with botanical and pharmaceutical dermatology products (A-Derma, Ducray, Avène) — comparable botanical/pharmaceutical hybrid positioning across women's health and dermatology categories.
• Almirall: Spanish dermatology-focused specialty pharma with portfolio across actinic keratosis, psoriasis, and atopic dermatitis — comparable specialty dermatology focus and partner-driven European distribution.
• Sinclair Pharma: Aesthetics-focused specialty pharma offering topical and injectable products across dermatology and women's health — comparable in therapeutic vertical mix and partner-distributed model.

Others

• Aurobindo Pharma: Large generic and OTC manufacturer with European and emerging-market distribution — comparable in wholesale pharmaceutical supply and presence across Benostan's stated geographies, though at much larger scale and with different go-to-market emphasis.

Broad incumbents

• Bayer Consumer Health: Major OTC consumer healthcare division with women's health, dermatology, and self-care brands — comparable OTC therapeutic verticals but vastly larger scale and direct-to-consumer infrastructure.
• Beiersdorf (Eucerin, La Prairie): German personal-care major with a dermocosmetics franchise (Eucerin, Aquaphor) — comparable medical-grade skincare positioning, though at vastly larger scale and broader consumer footprint.
• Haleon: Consumer healthcare spin-off from GSK with dermatology, oral health, and wellness brands — comparable OTC and self-care focus across multiple therapeutic verticals.

Regional players

• Hyphens Pharma: Singapore-based specialty pharma with proprietary and in-licensed products across Southeast Asia — comparable licensing/distribution model and footprint overlap in Benostan's stated Southeast Asian markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Benostan Health Products